Last reviewed · How we verify
NCT06277921: ESOSTAT
Morbidity and Mortality After Esophageal and Esophagogastric Junction Cancer Surgery
trial testing Elective Surgery for gastric cancer in Esophageal Cancer in 230 participants. Completed in 20 January 2025.
18 September 2024
Quick facts
| Lead sponsor | P. Herzen Moscow Oncology Research Institute |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 230 |
| Start date | 18 March 2024 |
| Primary completion | 18 September 2024 |
| Estimated completion | 20 January 2025 |
| Sites | 18 locations across Russia, Belarus |
Drugs / interventions tested
- Elective Surgery for gastric cancer
Conditions studied
- Esophageal Cancer — all drugs for Esophageal Cancer →
- Oesophageal Cancer — all drugs for Oesophageal Cancer →
- Siewert Type I Adenocarcinoma of Esophagogastric Junction — all drugs for Siewert Type I Adenocarcinoma of Esophagogastric Junction →
- Siewert Type III Adenocarcinoma of Esophagogastric Junction — all drugs for Siewert Type III Adenocarcinoma of Esophagogastric Junction →
Sponsor
P. Herzen Moscow Oncology Research Institute
Who can join
18 and older, any sex, with Esophageal Cancer or Oesophageal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Esophageal and esophagogastric junction cancer is still one of the main health care issue and esophagectomy with lymph node dissection is the only chance to be cure. However, esophagectomy for esophageal cancer is a complex procedure which carries high risk of morbidity rate of 24% and a mortality rate of 2% to 5.6%, respectively There is a need to study the differences of 90-day postoperative morbidity and mortality in different clinics and centers of the Russian Federation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06277921
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Elective Surgery for gastric cancer
Trials testing the same drug.
- NCT06277908 — Postoperative Morbidity and Mortality After Gastric Cancer Surgery · unknown
Other recruiting trials for Esophageal Cancer
Currently open trials in the same condition.
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting
Other P. Herzen Moscow Oncology Research Institute trials
Trials by the same sponsor.
- NCT07441785 — Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esopha · recruiting
- NCT06277908 — Postoperative Morbidity and Mortality After Gastric Cancer Surgery · unknown
- NCT06844409 — Neoadjuvant FOLFOX Chemotherapy for Colon Cancer: Long-Term Chemotherapy-Induced Peripheral Neuropathy and Impact on Qua · completed
- NCT07403916 — Influence of Age on the Choice of Treatment and Prognosis in Patients With Resectable Gastric Cancer · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06277921 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by P. Herzen Moscow Oncology Research Institute
- Last refreshed: 2 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06277921.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing